About this document
Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL - Long-Term Outcomes, Toxicity, and Pharmacokinetics by Juan Cruz is a document available to read on EtoBox.
The study evaluates the long-term outcomes of adding blinatumomab to standard chemotherapy in infants with KMT2A-rearranged acute lymphoblastic leukemia (ALL). Results show significant improvements in disease-free survival (DFS) and overall survival (OS) compared to historical controls, with a 4-year DFS of 83.3% and OS of 93.3%. The pharmacokinetics of blinatumomab were consistent across pediatric age groups, indicating its potential as a promising frontline therapy for this high-risk population.
- Author
- Juan Cruz
- Language
- EN